On June 1, 2023 Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, reported that it has signed an exclusive licensing agreement with Eikon Therapeutics (Press release, Seven and Eight Biopharmaceuticals, JUN 1, 2023, View Source [SID1234632375]). As part of the agreement, Eikon Therapeutics is awarded global rights to develop and commercialize the company’s novel immune modulator agonists targeting toll-like receptor 7 and 8 (TLR7/8).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have made great progress in the field of TLR7/8 agonists and advanced our molecules to industry leading positions," said Walter Lau, Ph.D., Chief Executive Officer of Seven and Eight Biopharmaceuticals. "We are delighted to have the Eikon team continue the clinical development and ultimate commercialization of these molecules. Eikon and its highly experienced immuno-oncology team has a proven track record of developing and commercializing industry leading anti-PD-1 therapies, and we believe they will be uniquely positioned to advance our first-in-class TLR7/8 agonists as potential treatments for multiple tumor types."

"The Seven and Eight Biopharma novel TLR7/8 agonists have, in Phase I trials, shown an acceptable safety profile in over 150 patients treated in mono- or in combination with anti-PD-(L)1 therapy," said Robert H.I. Andtbacka, M.D., C.M., Chief Medical Officer of Seven and Eight Biopharmaceuticals. "In addition, encouraging clinical responses have been seen in both mono- and combination therapy in multiple heavily pre-treated tumor types. We are excited to see the development of these novel TLR7/8 agonist continue under Eikon’s leadership."

The exclusive licensing agreement also includes development of novel Toll-like receptor ligand antibody conjugation (TLAC) molecules. "Over the years, Seven and Eight Biopharma has built not only TLR7/8 agonist programs from the ground up but also an innovative TLAC platform, and we are glad to see the continued development of these promising molecules" said Lixin Li, M.D., Ph.D., Chief Technical Officer of Seven and Eight Biopharmaceuticals.